Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Applied Therapeutics (APLT) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to 1675.8%.

  • Applied Therapeutics' EBITDA Margin rose 227037100.0% to 1675.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 9840.3%, marking a year-over-year decrease of 557527400.0%. This contributed to the annual value of 22922.86% for FY2024, which is 222770600.0% down from last year.
  • According to the latest figures from Q3 2025, Applied Therapeutics' EBITDA Margin is 1675.8%, which was up 227037100.0% from 24379.51% recorded in Q3 2024.
  • In the past 5 years, Applied Therapeutics' EBITDA Margin ranged from a high of 3149.63% in Q4 2023 and a low of 24379.51% during Q3 2024
  • In the last 3 years, Applied Therapeutics' EBITDA Margin had a median value of 6111.15% in 2025 and averaged 7958.08%.
  • As far as peak fluctuations go, Applied Therapeutics' EBITDA Margin crashed by -104446400bps in 2024, and later soared by 227037100bps in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' EBITDA Margin stood at 3149.63% in 2023, then crashed by -874bps to 24379.51% in 2024, then surged by 93bps to 1675.8% in 2025.
  • Its EBITDA Margin stands at 1675.8% for Q3 2025, versus 24379.51% for Q3 2024 and 14194.44% for Q2 2024.